We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




3-D Multiplexing System Simultaneously Measures up to 500 Analytes

By HospiMedica staff writers
Posted on 25 Jul 2007
A bead-based multiplexing system simultaneously measures up to 500 analytes in a single microplate well.

The new generation system, FlexMap 3D, provides clinicians, scientists, and researchers and with improved analytic capabilities that will enable users to broaden the types of testing performed with bead-based multiplexing. More...
The new instrument includes a high-throughput module and the ability to interface with liquid handlers for streamlined automation.

Luminex Corp. (Austin, TX, USA), a company that specializes in multiplexed systems, unveiled the FlexMap 3D at the American Association for Clinical Chemistry (AACC) annual meeting in San Diego (CA, USA), which took place on July 17-19, 2007. Patrick J. Balthrop, president and CEO of Luminex said, "[The] system features the same flexibility of our other instruments and provides increased speed, multiplexing, sensitivity, and automation.”

The ability to test for up to 500 analytes simultaneously is an increase from the 100-plex capabilities of Luminex's previous offerings. The FlexMap 3D system will also include digital technology, redesigned optics for improved assay performance, a dual syringe assembly to enhance throughput, an autoadjusting probe, software to enable automation, and the ability to use both 96- and 384-well plates. The new system is powered by xPonent 3D software, and features an intuitive touch screen interface as well as ergonomic design and a small footprint. Medium and high volume laboratories seeking more data per sample will benefit from the increased multiplexing capabilities.

Luminex systems are flexible analyzers based on the principles of three-dimensional (3D) bead arrays. Due to the enhanced liquid kinetics of the microspheres in solution, these arrays offer better uniformity and faster reaction times than standard 2D planar arrays. The microsphere dyeing process also provides higher levels of multiplexing than traditional methods such as the enzyme-linked immunosorbant assay (ELISA) or real-time polymerase chain reaction (RT-PCR). Luminex licenses its instruments and array-based assays to clinical diagnostic and biologic research companies

Currently undergoing alpha testing, FlexMap 3D is targeted to be commercially available in 2008.


Related Links:
Luminex

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Fetal Monitor
BT-380
Medical Adhesive
MED 5570U
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.